Other
Deferred charges related to intra-entity transfers
Vertex Pharmaceuticals Deferred charges related to intra-entity transfers remained flat by 0.0% to -0.3% in Q4 2025 compared to the prior quarter.
Analysis
StatementIncome Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Significant values suggest active tax planning or restructuring of internal asset ownership.
Detailed definition
This represents the tax reconciliation item specifically related to deferred charges from intra-entity asset transfers,...
Peer comparison
Standard reconciliation item for large multinational enterprises.
Metric ID:
other_effective_income_tax_rate_reconciliation_deferred__eeae32Historical Data
1 years
| FY'25 | |
|---|---|
| Value | -1.3% |
Deferred charges related to intra-entity transfers at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's deferred charges related to intra-entity transfers?
- Vertex Pharmaceuticals (VRTX) reported deferred charges related to intra-entity transfers of -0.3% in Q4 2025.
- What does deferred charges related to intra-entity transfers mean?
- A specific tax reconciliation adjustment for deferred charges related to internal asset transfers.